Sanofi puts new CSO in Boston, adding more weight to U.S. R&D

Sanofi's ($SNY) center of gravity is continuing its shift toward the U.S. The French drugmaker not only recruited a top official at the National Institutes of Health to be its chief scientific officer. It also decided to place him in the Boston area, where it set up an R&D hub last year. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.